Olfactory Biosciences and Fisher Healthcare Sign Distribution Agreement for NOXO™ Products
28 3월 2013 - 6:00PM
Access Wire
PHILADELPHIA - Olfactory Biosciences Corp (OTC: OLFC) today
announced that it has signed a distribution agreement with Fisher
HealthCare, part of Thermo Fisher Scientific Inc. (NYSE:TMO), for
its new and improved, all natural formulation for NOXO Odor
Defense™ and two other NOXO products. All products are immediately
available from Fisher Healthcare. NOXO is a special proprietary
formulation of Phytonutrients and Phytochemicals taken from plants,
flowers, roots and seeds, designed to have far-reaching
applications around the world for people who must endure noxious
smells.
NOXO is gel, applied topically under the nostrils, specifically
formulated to block the physical discomfort, retching, nausea and
vomiting associated with offensive and unpleasant odors. NOXO's
innovation is to control the effects of offensive and unpleasant
odors at the olfactory receptor site whereas other products attempt
to control bad odors at the source.
Uniquely formulated NOXO Odor Defense™ is based on advanced
olfactory perception altering technology developed by Dr. V Ruth
Pinney who is a director of Olfactory Biosciences Corp and who also
conducts the research for the company's products at her research
facility in The Woodlands Texas.
About Fisher HealthCare
Fisher HealthCare is a leading supplier of diagnostic tests,
equipment, chemicals, and other products used by national
laboratory networks, independent clinical laboratories, hospitals,
and physicians' offices. Information about Fisher HealthCare and
its products is available on the company's Web site at
www.fisherhealthcare.com.
About Olfactory Biosciences Corp
Olfactory Biosciences Corp.’s NOXO division is focused to
develop a variety of products targeting Olfactory Receptors for the
desired effect. These alternative medicine wellness products may
modify behavior or provide relief to common health problems such as
smoking cessation or weight control, as examples.
This company has taken NOBEL Prize science related to
discoveries of odorant receptors in the nose and the organization
of the olfactory system, and has developed unique wellness products
that are affordable and made from all natural ingredients.
Olfactory Biosciences Corp. offers the most advanced and innovative
wellness products with the potential to change the way we approach
wellness issues today. Olfactory Biosciences Corp’s unique
advantages will make NOXO products the most sought-after wellness
products in the alternative medicine market, creating a growth rate
ten times higher than most in the this growing category.
FORWARD-LOOKING STATEMENTS
"Safe Harbor" Statement under the PrivateSecurities Litigation
Reform Act of 1995: Statements by the Company, statementsregarding
the NOXO product line, optimism related to the business, expanding
ales and other statements in this press release are forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Such statements are based on current expectations,
estimates and projections about the Company's business. Words such
as expects, anticipates, intends, plans, believes, sees, estimates
and variations of such words and similar expressions are intended
to identify such forward-looking statements. These statements are
not guarantees of future performance and involve certain risks and
uncertainties that are difficult to predict. Actual results could
vary materially from the description contained herein due to many
factors including continued market acceptance of the Company's
products or the need to raise additional capital. In addition,
actual results could vary materially based on changes or slower
growth in the indoor garden market; the potential inability to
realize expected benefits and synergies; domestic and international
business and economic conditions; changes in customer demand or
ordering patterns; changes in the competitive environment including
pricing pressures or technological changes; technological advances;
shortages of manufacturing capacity; future production variables
impacting excess inventory and other risk factors listed from time
to time in the Company's Securities and Exchange Commission (SEC)
filings under "risk factors" and elsewhere. The forward-looking
statements contained in this press release speak only as of the
date on which they are made, and the Company does not undertake any
obligation to update any forward-looking statement to reflect
events or circumstances after the date of this press release.
Richard Stevenson
Olfactory Biosciences Corp.
333 E. Lancaster Ave. Suite 317
Wynnewood, PA 19096, USA
Phone: 484-278-1626
(USOTC:OLFC)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
(USOTC:OLFC)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
